Literature DB >> 2353192

Risk of spontaneous abortion among nurses handling antineoplastic drugs.

I Stücker1, J F Caillard, R Collin, M Gout, D Poyen, D Hémon.   

Abstract

The purpose of the study was to evaluate the frequency of spontaneous abortion in two groups of women. One group consisted of women regularly involved in the preparation of cancer chemotherapy perfusions and therefore considered to be exposed to cytostatic agents; the other consisted of women not occupationally exposed to such agents. The study was carried out in four French hospitals. Four hundred and sixty-six women were involved; 534 pregnancies were described in which 139 were exposed and 357 were unexposed. The results showed that the frequency of spontaneous abortion was 26% for the exposed pregnancies and 15% in the unexposed ones (odds ratio 2.0). These results do not seem to be due either to the classic risk factors of spontaneous abortion (age, cigarette consumption during pregnancy, pregnancy order) (adjusted odds ratio 1.7) or to possible errors concerning the retrospective evaluation of prior gynecologic and obstetric history.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2353192     DOI: 10.5271/sjweh.1811

Source DB:  PubMed          Journal:  Scand J Work Environ Health        ISSN: 0355-3140            Impact factor:   5.024


  21 in total

1.  Occupational exposures among nurses and risk of spontaneous abortion.

Authors:  Christina C Lawson; Carissa M Rocheleau; Elizabeth A Whelan; Eileen N Lividoti Hibert; Barbara Grajewski; Donna Spiegelman; Janet W Rich-Edwards
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

Review 2.  Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence.

Authors:  Thomas H Connor; Christina C Lawson; Martha Polovich; Melissa A McDiarmid
Journal:  J Occup Environ Med       Date:  2014-09       Impact factor: 2.162

3.  Inhalation and dermal exposure to eight antineoplastic drugs in an industrial laundry facility.

Authors:  Wouter Fransman; Daan Huizer; Jochen Tuerk; Hans Kromhout
Journal:  Int Arch Occup Environ Health       Date:  2006-10-05       Impact factor: 3.015

4.  Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs.

Authors:  Laurent Benoit; Nicolas Cheynel; Pablo Ortega-Deballon; Giovanni Di Giacomo; Bruno Chauffert; Patrick Rat
Journal:  Ann Surg Oncol       Date:  2007-10-10       Impact factor: 5.344

5.  Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.

Authors:  Paul J M Sessink; Thomas H Connor; James A Jorgenson; Timothy G Tyler
Journal:  J Oncol Pharm Pract       Date:  2010-02-15       Impact factor: 1.809

6.  Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs.

Authors:  A S Ensslin; Y Stoll; A Pethran; A Pfaller; H Römmelt; G Fruhmann
Journal:  Occup Environ Med       Date:  1994-04       Impact factor: 4.402

7.  Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities.

Authors:  Wouter Fransman; Roel Vermeulen; Hans Kromhout
Journal:  Int Arch Occup Environ Health       Date:  2005-05-11       Impact factor: 3.015

8.  Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.

Authors:  Paul J M Sessink; Jason Trahan; Joseph W Coyne
Journal:  Hosp Pharm       Date:  2013-03

9.  Reproductive and developmental hazards and employment policies.

Authors:  J D Johnston; G G Jamieson; S Wright
Journal:  Br J Ind Med       Date:  1992-02

10.  Leukaemia and reproductive outcome among nurses handling antineoplastic drugs.

Authors:  T Skov; B Maarup; J Olsen; M Rørth; H Winthereik; E Lynge
Journal:  Br J Ind Med       Date:  1992-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.